Moderna Stock Forecast, Price & News

+7.96 (+2.30 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume11.30 million shs
Average Volume19.92 million shs
Market Capitalization$141.98 billion
P/E Ratio282.88
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Moderna logo

About Moderna

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.67 out of 5 stars

Medical Sector

781st out of 2,221 stocks

Biological Products, Except Diagnostic Industry

121st out of 213 stocks

Analyst Opinion: 2.1Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Moderna (NASDAQ:MRNA) Frequently Asked Questions

Is Moderna a buy right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 3 sell ratings, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Moderna stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View analyst ratings for Moderna
or view top-rated stocks.

What stocks does MarketBeat like better than Moderna?

Wall Street analysts have given Moderna a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Moderna wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Moderna?

Moderna saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 14,330,000 shares, an increase of 21.1% from the May 31st total of 11,830,000 shares. Based on an average daily volume of 9,450,000 shares, the short-interest ratio is presently 1.5 days. Approximately 4.2% of the shares of the company are sold short.
View Moderna's Short Interest

When is Moderna's next earnings date?

Moderna is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Moderna

How can I listen to Moderna's earnings call?

Moderna will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its earnings results on Thursday, May, 6th. The company reported $2.84 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.04 by $0.80. The business earned $1.94 billion during the quarter, compared to analyst estimates of $2.48 billion. Moderna had a trailing twelve-month return on equity of 19.76% and a net margin of 21.90%. The business's revenue for the quarter was up 24112.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.35) earnings per share.
View Moderna's earnings history

How has Moderna's stock been impacted by Coronavirus?

Moderna's stock was trading at $23.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRNA stock has increased by 1,397.7% and is now trading at $353.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MRNA?

16 analysts have issued 1 year price targets for Moderna's shares. Their forecasts range from $80.00 to $250.00. On average, they expect Moderna's stock price to reach $177.86 in the next twelve months. This suggests that the stock has a possible downside of 49.7%.
View analysts' price targets for Moderna
or view top-rated stocks among Wall Street analysts.

Who are Moderna's key executives?

Moderna's management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board (Age 58, Pay $107.5k)
  • Mr. Stephane Bancel, CEO & Director (Age 48, Pay $3.86M)
  • Dr. Stephen Hoge, Pres (Age 45, Pay $1.26M)
  • Mr. David W. Meline, CFO & Principal Accounting Officer (Age 64, Pay $932.62k)
  • Dr. Tal Zaks, Chief Medical Officer (Age 55, Pay $1.25M)
  • Mr. Juan Andres, Chief Technical Operations & Quality Officer (Age 56, Pay $1.25M) (LinkedIn Profile)
  • Dr. John V. W. Reynders, Chief Information Officer
  • Dr. Melissa J. Moore, Chief Scientific Officer & Member of Scientific Advisory Board
  • Ms. Lavina Talukdar CFA, Sr. VP & Head of Investor Relations
  • Ms. Shannon Thyme Klinger, Chief Legal Officer & Corp. Sec. (Age 50)

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna CEO Stéphane Bancel on Stéphane Bancel has an approval rating of 92% among Moderna's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Moderna's key competitors?

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

When did Moderna IPO?

(MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

What is Moderna's stock symbol?

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Who are Moderna's major shareholders?

Moderna's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (0.24%), Alliancebernstein L.P. (0.05%), Oregon Public Employees Retirement Fund (0.03%), APEIRON CAPITAL Ltd (0.02%), Hodges Capital Management Inc. (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Moderna stock include Dustin A Moskovitz, Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Noubar Afeyan, Paul Sagan, Peter Barton Hutt, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks, Ventures Fund Iv Gene Flagship and W Don Cornwell.
View institutional ownership trends for Moderna

Which major investors are selling Moderna stock?

MRNA stock was sold by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, XR Securities LLC, Harel Insurance Investments & Financial Services Ltd., Meridian Wealth Management LLC, Golden Green Inc., Carnegie Capital Asset Management LLC, Tradewinds Capital Management LLC, and DAVENPORT & Co LLC. Company insiders that have sold Moderna company stock in the last year include Juan Andres, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Stephane Bancel, Stephen Hoge, and Tal Zvi Zaks.
View insider buying and selling activity for Moderna
or view top insider-selling stocks.

Which major investors are buying Moderna stock?

MRNA stock was acquired by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Hodges Capital Management Inc., APEIRON CAPITAL Ltd, Alliancebernstein L.P., IFM Investors Pty Ltd, Hillsdale Investment Management Inc., Patten & Patten Inc. TN, and Bellecapital International Ltd.. Company insiders that have bought Moderna stock in the last two years include Dustin A Moskovitz, Juan Andres, Paul Sagan, and W Don Cornwell.
View insider buying and selling activity for Moderna
or or view top insider-buying stocks.

How do I buy shares of Moderna?

Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Moderna's stock price today?

One share of MRNA stock can currently be purchased for approximately $353.60.

How much money does Moderna make?

Moderna has a market capitalization of $141.98 billion and generates $803.40 million in revenue each year. The company earns $-747,060,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis.

How many employees does Moderna have?

Moderna employs 1,300 workers across the globe.

What is Moderna's official website?

The official website for Moderna is

Where are Moderna's headquarters?

Moderna is headquartered at 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139.

How can I contact Moderna?

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-714-6500 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.